PRODUCT OVERVIEW & COMPOSITION
Brand / Manufacturer: Bioniche Pharma
Active Ingredient: Drostanolone Propionate (150 mg per ml)
Pharmacological Class: Synthetic Anabolic-Androgenic Steroid (Fast-acting Dihydrotestosterone / DHT derivative)
Bioniche Pharma Drostanolone Propionate 150 mg is a short-acting injectable anabolic agent derived from dihydrotestosterone (DHT). Formulated by Bioniche Pharma with a short propionate ester for rapid therapeutic onset, Bioniche Pharma Drostanolone Propionate delivers high anabolic selectivity without aromatizing into estrogen, making it an effective compound for lean muscle preservation and tissue recovery.
CLINICAL PHARMACOLOGY & MECHANISM OF ACTION
Bioniche Pharma Drostanolone Propionate acts by binding directly to nuclear androgen receptors to stimulate anabolic cellular pathways, improve nitrogen retention, and accelerate protein synthesis. As a non-aromatizable DHT derivative, Bioniche Pharma Drostanolone Propionate does not convert into estrogen, eliminating risks of estrogen-induced water retention and gynecomastia while exerting inherent anti-estrogenic effects.
INDICATIONS & CLINICAL USE
- Palliative treatment for advanced hormone-responsive breast carcinoma in postmenopausal females using Bioniche Pharma protocols.
- Therapeutic support to accelerate tissue repair and recovery following major physical trauma or surgery with Bioniche Pharma formulations.
- Adjunctive treatment in specialized cases of growth impairment under strict Bioniche Pharma medical supervision.
CONTRAINDICATIONS
- Confirmed or suspected carcinoma of the male breast or prostate gland.
- Female breast carcinoma complicated by severe hypercalcemia (elevated blood calcium levels).
- Severe renal dysfunction or advanced hepatic disease.
- Pregnancy and lactation due to serious risks of fetal harm and virilization.
- Known hypersensitivity to Bioniche Pharma Drostanolone Propionate, carrier oils, or inactive components in Bioniche Pharma formulations.
PRECAUTIONS & METABOLIC MONITORS
- Glycemic Monitoring: Anabolic steroids may alter glucose tolerance and insulin sensitivity. Diabetic patients should check blood or urine glucose levels frequently during Bioniche Pharma therapy, as antidiabetic medications may require dosage adjustments.
- Pediatric Caution: Extreme caution is advised if Bioniche Pharma products are administered to pediatric patients due to heightened sensitivity to androgenic effects and potential premature epiphyseal closure.
- Lipid & Hepatic Surveillance: Routine monitoring of serum lipid profiles (HDL/LDL) and hepatic enzymes is recommended throughout Bioniche Pharma treatment.
ADVERSE REACTIONS
- Dermatological & Androgenic: Oily skin, acne vulgaris, accelerated facial/body hair growth (hirsutism), and androgenetic alopecia (male pattern baldness) in genetically predisposed individuals receiving Bioniche Pharma therapy.
- Endocrine & Systemic: Reversible suppression of endogenous gonadotropin secretion and potential virilization manifestations in female patients upon prolonged exposure to Bioniche Pharma formulations.
DOSAGE & ADMINISTRATION
To maintain stable serum hormone concentrations, Bioniche Pharma Drostanolone Propionate is administered via deep intramuscular injection 2 to 3 times per week. The total weekly dosage of Bioniche Pharma Drostanolone Propionate typically ranges between 150 mg and 450 mg, as individualized and supervised by a qualified physician based on clinical objective and patient response.
STORAGE & HANDLING
Store Bioniche Pharma injectable products in a cool, dry place shielded from direct light exposure and excess heat. Do not refrigerate or freeze Bioniche Pharma products. Keep strictly out of reach and sight of children.